AnaptysBio (ANAB) stock

Antibody candidates , market cap $1.4B

Antibody candidates

Worth $1.4B

$48.38

+0.85%

FDA in 32 daysEvery upcoming FDA date ›

As of Tuesday's close · Live for Pro members at the open

Quality Score

Average

In its industry

#59of 281

Biotech

Checks firing

4of 14

Trending down

From 52-week high

-34.0%

under its best in a year

ANAB's Quality Score rose 1 point on Tue, Nov 10, to 8. It closed near its high of the day (2 chart checks started).

Follow ANAB's trial news. Pro members can get an alert when AnaptysBio files news, and see its trials, share raises, and its CEO's filings.

Get an alert when ANAB files news on its trialsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextDec 12, 2026 · In 32 days“FDA target action date (PDUFA) of Dec. 12, 2026, for Quimilza in generalized pustular psoriasis (GPP)”Vanda’s FDA decision date · SEC filing · Sep 21

Why is ANAB up?

Up 222% over three years while the S&P 500 rose 80%.

Its loss narrowed from $145.2M in fiscal 2024 to $13.2M in fiscal 2025; free cash flow went from -$74.0M to $19.6M.

Sources: Price history, Nov 9, 2026; Annual reports, Dec 31, 2025

1 more reason, free with an account →The timeline and its peers, for Pro members.

Key facts on ANAB

Key facts on ANAB
The company	Sales up 93% on the year
Latest filing	10-Q, Sep 21 Filed its quarterly report (10-Q) for the quarter to Jun 30, 2026

1 more reason behind ANAB's 8, free with an account →1 more reason behind ANAB's 8, for Pro members.

ANAB in the news

ReportExpected to report tomorrow, after the close. Every 3 months, a company tells everyone how much it sold and earned. It rose after 2 and fell after 2 of its last 4 reports, +3.0% on average. Past reports ›

Big story

FDA

AnaptysBio Announces FDA Approval of GSK's Jemperli for MSI-H/dMMR Locally Advanced Rectal Cancer Based on AZUR-1 Data

ANAB closed +5.6% that day.

Reported by quiver quantitative · covered by 2 outlets

Get an alert on ANAB's next big story →

What's next

Tue Nov 17: UBS Global Biopharma Conference 2026Investor conference · date confirmed.

2 more dates ahead: conferences, for Pro members.

ANAB catalysts

Coming up

After its last 4 reports it closed +3.0% on average, higher 2 of 4 times.

9 past catalysts since 2020, with sizes and sources, for Pro members.

What's next for ANAB

Next step the company has named

Dec 12In 32 days“FDA target action date (PDUFA) of Dec. 12, 2026, for Quimilza in generalized pustular psoriasis (GPP)”Vanda’s FDA decision date · SEC filing · Sep 21

What it means: the date by which the FDA has said it aims to decide on Vanda’s application, which ANAB is partnered on. The FDA can decide earlier, or extend the date.

2 more trials, 38 filings, for Pro members.

Dilution on the horizon

Shelf registration (S-3, filed Nov 5, 2024)
At-the-market share sales program (424B5, filed Nov 15, 2024)

For Pro members: 2 raises and their amounts, and the share count against a year ago.

Insiders

Director Hollings Renton sold 5,000 shares on Oct 1, under a planned sale. 16 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Daniel Faga buys or sells

For Pro members: every trade, and Daniel Faga’s 16 filings and quotes.

Get an alert when ANAB files news on its trialsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

Why ANAB scores 8

Averagefor quality, not price, 4 of 14 chart checks firingWhat the Quality Score means

+4Chart checks 4 of 14 firing right now, one point each
+3Growth sales up 93% on the year, operating margin up 54.6 pointsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.

Long-term trend subtracts
Profit addsRead on the last four quarters against the four before, or the last full year where no quarters are filed.

No effect today: Run-up, Size, Dilution, Volatility, Cash flow, Persistence, and News.

What every line is worth, and the reason behind it, on ANAB and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 11:29 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when ANAB's Quality Score turns up

A free account. No card.

How ANAB ranks in Biotech

ANAB is #59 of 281 by Quality Score.

How ANAB ranks in Biotech
Rank	Stock	Checks	Quality Score
1	ONCBeOne Medicines	8/14	24
2	VCELVericel	8/14	22
3	ETONEton Pharmaceutcials	9/14	20
	AMPHAmphastar Pharmaceuticals		Open for its score
	AMRXAmneal Pharmaceuticals		Open for its score
	ANIPANI Pharmaceuticals		Open for its score
	AQSTAquestive Therapeutics		Open for its score
59	ANABAnaptysBio	4/14	8

When does ANAB report earnings, and what happens after?

Expected to report Wed Nov 11, after the close (tomorrow).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

Close after the report, last 3

+14.6%-4.4%-1.8%

Mar 3May 12Sep 21

Reported	When	Gap	Reaction	5 days
Sep 21, 2026After close	After close	+0.3%	-1.8%	-7.5%
May 12, 2026After close	After close	-0.7%	-4.4%	-8.9%
Mar 3, 2026After close	After close	+6.2%	+14.6%	+17.4%

ANAB closed higher after 2 of its last 4 reports.

All 4 reports, and ANAB's Quality Score going into each

Everyone reporting earnings this week

ANAB sales and profit by year

Sales and profit by year

Sales grew in five of the last seven years, to $235M in 2025. It lost money in each of the eight years.

ANAB has 4 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on ANAB, and all 14 on every stock.Get in free →

ANAB RSI today: 49.8, below its 50-day and 200-day averages

Not scored

RSI 49.8, MACD above signal, below both averages. Not scored.13 readings

The deep dive on ANAB

What it does and how it makes money3 findingsIt kept 97 cents of each dollar of sales in fiscal 2025: $227M of operating profit on $235M of sales.Annual report, filed Mar 3, 2026
Where it stands2 findingsFor Pro members2 findings on where ANAB stands: its cash, debt, and share count, for Pro members
What changed in its filings5 findings"On November 20, 2025, we filed a Verified Complaint in Delaware Chancery Court (the 'Court'), requesting a court declaration that TESARO …" (10-Q for the quarter to Mar 31, 2026)SEC filing · May 12, 2026A new heading in its "Risk Factors" this year: "Some of our suppliers may experience disruption to their respective supply chain due to the effects of macroeconomic conditions, which could delay, prevent or impair our development or commercialization efforts." (10-K for fiscal 2025; not in fiscal 2024's)SEC filing · Mar 3, 2026, against the one of Feb 27, 2025
Who holds and trades it1 findingFor Pro members1 finding on who holds and trades ANAB, for Pro members

8 more findings on ANAB, each with its source, for Pro members.

ANAB share count over time

Shares: 2.5% fewer than a year ago (to Jun 30).

Shares of ANAB outstanding, as filed
Shares outstanding	As of
29.9M	Sep 16, 2026
29.1M	May 7, 2026
29.1M	Apr 23, 2026
28.7M	Feb 27, 2026

Offerings, shelves, and splits of ANAB, from its filings
From its filings	Filed
Set up an at-the-market program for up to $100M of shares, about 7% of its market value	Nov 15, 2024
Registered shares for a later sale (S-3)	Nov 5, 2024
Priced a sale of shares	Aug 14, 2024

ANAB's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Daniel FagaPresident, CEO · 13 trades
Dennis MulroyChief Financial Officer · 5 trades
Eric J. LoumeauChief Legal Officer · 11 trades
Paul F. LizzulChief Medical Officer · 4 trades
John P. SchmidDirector · 3 trades
Magda MarquetDirector · 2 trades
Hollings RentonDirector · 1 trade
J. Anthony WareDirector · 1 trade

One more officer or director files at ANAB.

See insider trades by person

Which ETFs hold ANAB?

In ETFs: ANAB is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About AnaptysBio

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

104 employeesSan Diego, CAanaptysbio.com

What AnaptysBio says it competes with

“The biotechnology and pharmaceutical industries are characterized by continuing technological advancement and significant competition.”

From its annual report, SEC filing · Mar 3, 2026

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on ANAB and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would turn ANAB's score around: 4 things
4 more filings explained, a plain line each
Real-⁠time prices, no delay

See ANAB's 14 chart checks

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: ANAB's Quality Score is 8 (Average), #59 of 281 in Biotech.

What does ANAB's Quality Score say?

ANAB scores 8 today, which Breakaway calls Average. It is #59 of 281 in Biotech by Quality Score, with 4 of 14 chart checks firing. Up 222% over three years while the S&P 500 rose 80%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is ANAB's Quality Score?

ANAB scores 8 today, which Breakaway calls Average (6 to 10). That is #59 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ANAB's 8.

When does ANAB report earnings?

Expected to report Wed Nov 11, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. ANAB closed higher after 2 of its last 4 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.